TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03116620

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chewing evaluation
Description: Children with neuromuscular disorders (NMD) will be participated. Children will be asked to chew a standardized biscuit while video recording. Two physical therapists will assess all video recordings independently and score each video according to the KCPS. The correlation between the KCPS scores of two therapists will be used for interobserver reliability. One therapist will rescore the recordings after an interval of 2 weeks for intraobserver reliability.
Study: NCT02811263

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline placebo
Description: Equal volume of normal saline to be used as placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythropoietin
Description: Epogen drawn from commercially available single dose 4000U/mL vials
Study: NCT04177563

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole body cryostimulation
Description: Whole-body cryotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole body cryostimulation
Description: Whole-body cryotherapy
Study: NCT03623334

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image-Guided Radiation Therapy
Description: Radiotherapy to a potent tumorcidal dose
Study: NCT04632537

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tice® BCG (for intravesical use) BCG LIVE strain of the BCG (Merck) vaccine
Description: Tice® BCG (for intravesical use) BCG LIVE strain of the BCG (Merck) vaccine will be diluted in preservative-free saline and given intradermally (0.1mL) in the deltoid area.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Preservative-free saline
Description: Placebo will be administered in an intradermal route in the same location as the BCG vaccines: upper arm. Placebo will comprise 0.1 mL of the diluent (preservative-free saline) to ensure the same quantity and same color as the resuspended BCG vaccine, rendering the two indistinguishable.
Study: NCT02886195

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed
Description: 500mg/m2 ivgtt d1, per three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500mg/m2 ivgtt d1, per three weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: 80mg/m2 ivgtt d1, per three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 80mg/m2 ivgtt d1, per three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150mg po. every day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: 150mg po. every day
Study: NCT03508661

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SPIN-SSLED Program
Description: The program includes 13 modules that will be delivered live via webinar over the course of the 3-month program. Each module will be delivered in a 60- to 90-minute session. Module topics include (1) the leader's role; (2) starting a support group; (3) structuring a support group meeting; (4) scleroderma 101; (5) successful support group culture; (6 \&7) managing support group dynamics I and II; (8) grief and crisis in scleroderma; (9) marketing and recruitment; (10) the continuity of the group; (11) supporting yourself as a leader; (12) virtual support group meetings, (13) support group leader resources. Participants will receive a workbook, be shown filmed vignettes, and will have access to an online resource center.
Study: NCT00709033

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous or syngeneic PBTLs and EBV-CTLs
Description: Three dose levels are being evaluated namely:~GROUP 1~PBTL CD19CAR-28 zeta 2x10exp7 cells/m2 and EBV-CTL CD19CAR zeta 2x10exp7 cells/m2~GROUP 2~PBTL CD19CAR-28 zeta 1x10exp8cells/m2 and EBV-CTL CD19CAR zeta 1x10exp8 cells/m2~GROUP 3~PBTL CD19CAR-28 zeta 2x10exp8 cells/m2 and EBV-CTL CD19CAR zeta 2x10exp8 cells/m2
Study: NCT03569306

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENB
Description: ENB is carried out by a ENB system（LungCare, China) which can offer real-time navigation for bronchoscopy reaching peripheral pulmonary nodules.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EBUS-GS
Description: EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm and a GS (K-201; Olympus).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EBUS-GS
Description: EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm and a GS (K-201; Olympus).
Study: NCT02585999

Intervention type: DEVICE
Group type: OTHER
Intervention: Xulane Contraceptive Patch
Description: Extended use (12 weeks) of contraceptive patch
Study: NCT01593579

Intervention type: BEHAVIORAL
Intervention: Autonomic Function Tests
Description: Patients will undergo Autonomic Function testing (AFT) before and 8 hours after Akt Inhibition therapy. AFT includes: Supine \& standing heart rate \& blood pressure, 10 minute head up tilt, cardiac output, sinus arrhythmia, hyperventilation, sustained handgrip, valsalva manuever, and cold pressor test.

Intervention type: OTHER
Intervention: supine and standing catecholamines
Description: patients will have blood drawn from supine and standing catecholamines.
Study: NCT03582735

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nerve gliding exercise
Description: A 4-week home-based nerve-gliding exercise program (NGEP) including isolated and coupled upper limb and neck movements. A specific mobilization was elaborated for each week of the program allowing to gradually increase the range of movement and inter-articular coordination.
Study: NCT00363051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg
Description: Participants took two 5 mg tablets of Everolimus orally with a glass of water, once daily (preferably in the morning) in a fasting state or after no more than a light, fat-free meal. Dosing was to occur at the same time each day. If vomiting occurred, the vomited dose was not to be replaced.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide Depot
Study: NCT02212002

Intervention type: DRUG
Intervention: IAP
Description: maternal IAP, consisting of intravenous ampicillin given every 4 hours until delivery (first dose 2 g, following doses 1 g each).
Study: NCT02581163

Intervention type: DRUG
Intervention: Ombitasvir/paritaprevir/ritonavir
Description: Co-formulated tablet

Intervention type: DRUG
Intervention: Dasabuvir
Description: Tablet

Intervention type: DRUG
Intervention: Ribavirin
Description: Tablet
Study: NCT01809665

Intervention type: DEVICE
Intervention: ICD/CRT-P therapy

Intervention type: OTHER
Intervention: MRI
Study: NCT01926743

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Near infrared fluorescence imaging during laparoscopic or robotic gastrectomy
Description: 0.75mg of ICG injection around tumor each four direction by endoscopy on one or two days before surgery. NIR fluorescence imaging application during laparoscopic or robotic gastrectomy
Study: NCT02292537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nusinersen
Description: Administered by intrathecal (IT) lumbar puncture (LP) injection

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: Small needle prick on the lower back at the location where the IT injection is normally made
Study: NCT00997490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neurapas® balance (Herbal combination out of hypericum, valerian, passionflower)
Description: 3 x 2 tablets/day over 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: film-coated sugar-pill
Description: 3 x 2 tablets / day over 6 weeks
Study: NCT03776500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBTZ169
Description: PBTZ169 crystalline supplied as powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBTZ169
Description: PBTZ169 crystalline supplied as powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBTZ169
Description: PBTZ169 crystalline supplied as powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBTZ169
Description: PBTZ169 crystalline supplied as powder for oral solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo supplied as powder for oral solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo supplied as powder for oral solution
Study: NCT00003645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutamide
Description: 10.8 mg intramuscularly once every 3 months for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: 50 mg tablet orally daily for 12 months
Study: NCT03280368

Intervention type: OTHER
Intervention: Bloodtest

Intervention type: OTHER
Intervention: Bloodtest

Intervention type: OTHER
Intervention: Bloodtest

Intervention type: OTHER
Intervention: Bloodtest

Intervention type: OTHER
Intervention: Questionnaires

Intervention type: OTHER
Intervention: Questionnaires
Study: NCT00205699

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risperidone
Description: randomized to begin 12 week trial of risperidone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: randomized to begin 12 week trial of olanzapine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aripiprazole
Description: randomized to 12 week trial of aripiprazole
Study: NCT03053726

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Variable Frequency Stimulation
Description: vary the frequency of the stimulation parameter
Study: NCT03516279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT04099979

Intervention type: OTHER
Intervention: No Intervention
Description: There is no intervention for this study
Study: NCT03053726

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Variable Frequency Stimulation
Description: vary the frequency of the stimulation parameter
Study: NCT04230798

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Injury prevention program
Description: The intervention program consisted in 16 sessions, performed during eight weeks, twice per week. Intervention group performed 20 minutes sessions before their habitual volleyball training. The structure of the prevention program consisted in a warm up, a lower limb strength exercise; two core exercises; a lower limb plyometric exercise, and a lower limb stability exercise. While the injury prevention program was being performed, both groups continued with their volleyball training sessions.
Study: NCT03678376

Intervention type: OTHER
Group type: OTHER
Intervention: complaint, cognitive and functional assessments
Description: The evaluation with their GP is composed of (1-) Clinical impression, (2-) GP-Cog part 2 with patient or their informal caregiver and (3-) 6-CIT test.~The identification of patients at risk of NCD with the new strategy applied by the GP will be compared to the gold standard for diagnosis of NCD at the Memory Clinic, established according to Diagnosis and Statistical Manual of mental disorders (DSM-5) criteria and based on a clinical, neuropsychological evaluation and functional abilities. If needed, a secondary etiological diagnosis procedure will be undertaken following the HAS 2011 recommendation including brain MRI and biology.
Study: NCT03955471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib is a potent, orally active poly (adenosine diphosphate-ribose) polymerase (PARP)-1 and PARP2 inhibitor being developed as a treatment for participants with tumors that harbor defects in the homologous recombination deoxyribonucleic acid (DNA) repair pathway or that are driven by PARP-mediated transcription factors.
Study: NCT02334670

Intervention type: DRUG
Intervention: Fluconazole
Description: HIV-infected patients with CD4 ≤100 cells/μL who present for HIV care at outpatient clinics (OPCs) in Vietnam where CrAg screening is offered will be recruited into the study. Study participants will be screened for cryptococcal antigen using the Lateral Flow Assay (LFA). Those who are CrAg-positive, but have no features of central nervous system (CNS) disease, will be treated with high-dose fluconazole.
Study: NCT03955471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: TSR-042 is a humanized monoclonal antibody that binds with high affinity to programmed cell death-1 (PD-1) resulting in inhibition of binding to programmed cell-death receptor ligands 1 and 2 (PD-L1 and PD-L2).
Study: NCT01310673

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Allopurinol 300mg po QD for 30 days.~Indomethacin 50mg TID for 10 days. Colchicine 0.6mg po Bid or QD, as tolerated for 90 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet QD for 10 days, followed by delayed allopurinol 300mg po QD days 11-30.~Indomethacin 50mg TID for 10 days. Colchicine 0.6mg po Bid or QD, as tolerated for 90 days.
Study: NCT01359644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSI-7977
Description: Tablets, oral, 400 mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSI-7977
Description: Tablets, oral, 400 mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSI-7977
Description: Tablets, oral, 400 mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSI-7977
Description: Tablets, oral, 400 mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSI-7977
Description: Tablets, oral, 400 mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSI-7977
Description: Tablets, oral, 400 mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSI-7977
Description: Tablets, oral, 400 mg, once daily
Study: NCT01581788

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Divalproex Sodium
Description: Divalproex Sodium ER Tablets, 500 mg
Study: NCT01969942

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic stem cell transplantation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic stem cell transplantation
Study: NCT03776500

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo supplied as powder for oral solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo supplied as powder for oral solution
Study: NCT01969942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabina

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Study: NCT04409652

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Head on bed
Description: During emergence, head is kept on bed without pillow.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Head on pillow
Description: During emergence, head is kept on pillow.
Study: NCT01091909

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental extractions
Description: All dental extractions were performed at an outpatient clinic at the USP Dental School. In addition, all extractions were performed under local anesthesia by the same experienced dentist, in accordance with the standards established by Peterson et al (2008).
Study: NCT02500394

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ionosteril
Description: biomarker guided volume substitution with Ionosteril

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ionosteril
Description: biomarker guided volume substitution with Ionosteril
Study: NCT03115112

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bexagliflozin
Description: tablets containing 20 mg bexagliflozin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: tablets containing 100 mg sitagliptin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for sitagliptin
Description: inactive tablets to match the appearance of sitagliptin tablets
Study: NCT00494182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Given PO
Study: NCT04055753

Intervention type: DRUG
Intervention: Doxil
Description: Doxil 50 mg/m2, as per institutional standard
Study: NCT01581788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex Sodium
Description: Divalproex Sodium ER Tablets, 500 mg
Study: NCT04407364

Intervention type: DEVICE
Intervention: CoMatryx Surgical Bovine Collagen
Description: The CoMatryx surgical collagen powder is a soft tissue repair product made of 100% type I bovine collagen

Intervention type: DEVICE
Intervention: CoMatryx Surgical Bovine Collagen
Description: The CoMatryx surgical collagen powder is a soft tissue repair product made of 100% type I bovine collagen
Study: NCT04055753

Intervention type: DRUG
Intervention: Doxorubicin
Description: Doxorubicin 75 mg/m2, IV over 5-15 min OR Continuous infusion over 48-72 hours
Study: NCT03115112

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for bexagliflozin
Description: inactive tablets to match the appearance of bexagliflozin tablets
Study: NCT05565976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg Tab
Description: 10mg PO q24h for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statins (Cardiovascular Agents)
Description: Atorvastatin 20mg PO q24h or Pravastatin 20mg PO q24h or Rosuvastatin 10mg PO q24h
Study: NCT01359644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSI-7977
Description: Tablets, oral, 400 mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSI-7977
Description: Tablets, oral, 400 mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSI-7977
Description: Tablets, oral, 400 mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Tablets, oral, 60 mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Tablets, oral, 60 mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Tablets, oral, 60 mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Tablets, oral, 60 mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Tablets, oral, 60 mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Tablets, oral, 60 mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Tablets, oral, 60 mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Tablets, oral, 60 mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Tablets, oral, 60 mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Tablets, oral, 60 mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablets, oral, 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablets, oral, 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablets, oral, 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablets, oral, 200 mg
Study: NCT02310646

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 90100 Aerosol Foam
Description: Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate) Aerosol Foam 60 g per can, applied once daily for one week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 90100 Aerosol Foam
Description: Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate) Aerosol Foam 60 g per can, applied once daily for one week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daivobet® gel
Description: Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate) Gel 60 g per bottle, applied once daily for one week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daivobet® gel
Description: Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate) Gel 60 g per bottle, applied once daily for one week.
Study: NCT04775420

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of mean platelet volume (MPV) and blood neutrophil to lymphocyte ratio (NLR)
Description: MPV and NLR are easily accessible and inexpensive tests

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of mean platelet volume (MPV) and blood neutrophil to lymphocyte ratio (NLR)
Description: MPV and NLR are easily accessible and inexpensive tests
Study: NCT00931268

Intervention type: DEVICE
Group type: OTHER
Intervention: Macrolane VRF 30
Description: One administration
Study: NCT00608517

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Given daily for 1-4 days